MORPHOSYS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.85 EUR | +0.15% |
|
+0.22% | +99.56% |
| Apr. 11 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
| Apr. 11 | Trending : Novartis Begins Tender Offer for MorphoSys Shares | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,021 | 3,072 | 1,139 | 451 | 1,278 | 2,555 | - | - |
| Enterprise Value (EV) 1 | 3,791 | 2,299 | 470.7 | -116.7 | 1,278 | 2,449 | 2,315 | 2,017 |
| P/E ratio | -38.9 x | 31.6 x | -2.17 x | -2.99 x | -6.15 x | -16 x | -32.9 x | 521 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 56 x | 9.37 x | 6.34 x | 1.62 x | 5.36 x | 10.2 x | 7.86 x | 6.09 x |
| EV / Revenue | 52.8 x | 7.02 x | 2.62 x | -0.42 x | 5.36 x | 9.74 x | 7.12 x | 4.81 x |
| EV / EBITDA | -37.3 x | 64.4 x | -1.76 x | 0.56 x | -5.28 x | -14.5 x | -22.7 x | -60 x |
| EV / FCF | -45.5 x | 74.6 x | -0.97 x | 0.32 x | -4.32 x | -8.28 x | -8.96 x | - |
| FCF Yield | -2.2% | 1.34% | -103% | 316% | -23.2% | -12.1% | -11.2% | - |
| Price to Book | 10.2 x | 4.95 x | 4.64 x | 2.87 x | 26.1 x | -11.4 x | 12.9 x | 3.62 x |
| Nbr of stocks (in thousands) | 31,708 | 32,739 | 34,141 | 34,141 | 37,593 | 37,663 | - | - |
| Reference price 2 | 126.8 | 93.82 | 33.35 | 13.21 | 34.00 | 67.85 | 67.85 | 67.85 |
| Announcement Date | 3/18/20 | 3/15/21 | 3/16/22 | 3/15/23 | 3/13/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 71.76 | 327.7 | 179.6 | 278.3 | 238.3 | 251.6 | 324.9 | 419.7 |
| EBITDA 1 | -101.7 | 35.69 | -267.5 | -210.2 | -241.9 | -169.5 | -102.2 | -33.61 |
| EBIT 1 | -107.9 | 27.36 | -277.6 | -220.7 | -252.5 | -180.2 | -82.12 | 29.21 |
| Operating Margin | -150.4% | 8.35% | -154.57% | -79.32% | -105.96% | -71.63% | -25.27% | 6.96% |
| Earnings before Tax (EBT) 1 | -106.5 | 22.49 | -591.1 | -319.6 | -190.9 | -147.6 | -88.01 | 17.45 |
| Net income 1 | -103 | 97.89 | -514.5 | -151.1 | -189.7 | -181.9 | -114.8 | -15.15 |
| Net margin | -143.56% | 29.87% | -286.47% | -54.29% | -79.61% | -72.29% | -35.33% | -3.61% |
| EPS 2 | -3.260 | 2.970 | -15.40 | -4.420 | -5.530 | -4.230 | -2.063 | 0.1302 |
| Free Cash Flow 1 | -83.24 | 30.81 | -485.3 | -368.6 | -296.2 | -295.8 | -258.3 | - |
| FCF margin | -116.01% | 9.4% | -270.19% | -132.48% | -124.29% | -117.59% | -79.5% | - |
| FCF Conversion (EBITDA) | - | 86.34% | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 31.48% | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/18/20 | 3/15/21 | 3/16/22 | 3/15/23 | 3/13/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 269.7 | 41.24 | 52.9 | 41.5 | 59.4 | 95.8 | 81.6 | 62.3 | 53.2 | 63.8 | 59 | 55.37 | 49.86 | 51.52 | 54.57 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -79.34 | - | - | - | - | - |
| EBIT 1 | 163.5 | -82.36 | -94.3 | -68 | -55.1 | -29.3 | -68.37 | -69.5 | -50.5 | -51 | -81.4 | -35.36 | -41 | -39.7 | -37.87 | - |
| Operating Margin | 60.63% | -199.68% | -178.26% | -163.86% | -92.76% | -30.58% | -83.79% | -111.56% | -94.92% | -79.94% | -137.97% | -63.87% | -82.22% | -77.06% | -69.4% | - |
| Earnings before Tax (EBT) 1 | - | -113 | - | -122.7 | - | -123 | - | -44.4 | -74 | -119.1 | 46.7 | -36.53 | -36.53 | -46.53 | -50.53 | - |
| Net income 1 | 179.8 | -112.8 | - | -122.7 | -235 | -122.9 | 329.4 | -44.4 | -74 | -119.6 | 48.3 | -46.42 | -49.08 | -56.95 | -61.18 | - |
| Net margin | 66.66% | -273.42% | - | -295.66% | -395.62% | -128.29% | 403.74% | -71.27% | -139.1% | -187.46% | 81.86% | -83.84% | -98.44% | -110.54% | -112.12% | - |
| EPS 2 | 5.540 | -3.300 | -11.16 | -3.590 | -6.880 | -3.600 | 9.650 | -1.300 | -2.160 | -3.500 | 1.220 | -0.3053 | -1.246 | -1.055 | -1.391 | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/5/20 | 11/10/21 | 3/16/22 | 5/4/22 | 8/3/22 | 11/16/22 | 3/15/23 | 5/3/23 | 8/9/23 | 11/15/23 | 3/13/24 | - | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 230 | 772 | 668 | 568 | - | 106 | 241 | 538 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -83.2 | 30.8 | -485 | -369 | -296 | -296 | -258 | - |
| ROE (net income / shareholders' equity) | -23.3% | 19.3% | -65.5% | -75.1% | -184% | - | -453% | - |
| ROA (Net income/ Total Assets) | -19.9% | 9.08% | -24.4% | -6.1% | -8.58% | -12.9% | -8.29% | - |
| Assets 1 | 517.6 | 1,078 | 2,108 | 2,477 | 2,211 | 1,406 | 1,384 | - |
| Book Value Per Share 2 | 12.40 | 19.00 | 7.190 | 4.610 | 1.300 | -5.980 | 5.270 | 18.80 |
| Cash Flow per Share | -2.540 | 1.060 | -14.40 | -10.70 | - | - | - | - |
| Capex 1 | 3.1 | 4.46 | 3.81 | 1.93 | 2.87 | 6.76 | 5.66 | 5.68 |
| Capex / Sales | 4.32% | 1.36% | 2.12% | 0.69% | 1.21% | 2.69% | 1.74% | 1.35% |
| Announcement Date | 3/18/20 | 3/15/21 | 3/16/22 | 3/15/23 | 3/13/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
67.85
EUR
Average target price
58.71
EUR
Spread / Average Target
-13.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +99.56% | 2.73B | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- MOR Stock
- Financials MorphoSys AG
